0001879785-21-000009.txt : 20211020
0001879785-21-000009.hdr.sgml : 20211020
20211020185617
ACCESSION NUMBER: 0001879785-21-000009
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211018
FILED AS OF DATE: 20211020
DATE AS OF CHANGE: 20211020
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kumar Ramesh
CENTRAL INDEX KEY: 0001580074
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36751
FILM NUMBER: 211335224
MAIL ADDRESS:
STREET 1: 375 PHEASANT RUN
CITY: NEWTOWN
STATE: PA
ZIP: 18940
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ocugen, Inc.
CENTRAL INDEX KEY: 0001372299
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 263 GREAT VALLEY PARKWAY
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: 484-328-4701
MAIL ADDRESS:
STREET 1: 263 GREAT VALLEY PARKWAY
CITY: MALVERN
STATE: PA
ZIP: 19355
FORMER COMPANY:
FORMER CONFORMED NAME: HISTOGENICS CORP
DATE OF NAME CHANGE: 20060810
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2021-10-18
0001372299
Ocugen, Inc.
OCGN
0001580074
Kumar Ramesh
C/O OCUGEN, INC.
263 GREAT VALLEY PARKWAY
MALVERN
PA
19355
1
0
0
0
Common Stock
2021-10-18
4
M
0
7500
0.510
A
7500
D
Common Stock
2021-10-18
4
S
0
7500
8.13
D
0
D
Option (Right to Buy)
0.51
2021-10-18
4
M
0
7500
0
D
2030-01-02
Common Stock
7500
31500
D
This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.10 to $8.14. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The option, initially representing a right to purchase 54,000 shares, vests and becomes exercisable in equal monthly installments over three years commencing on February 2, 2020, subject to continued service with the Company on the applicable vesting dates.
/s/ Ramesh Kumar by Sanjay Subramanian, his attorney-in-fact
2021-10-20